

A Study On Serum Digoxin Level :
Analytical Evaluation And Clinical Implications
In A Sample Of Egyptian Patients On Digoxin
Therapy

*Thesis Submitted For Partial Fulfilment
Of The Degree Of Doctor Of Medicine*

By

Dahlia Helmi Mohamed Farag
M.B., B.Ch., M.S.



Supervisors

Dr. Sawdan Hosney Hamza
Prof. of Clinical Pathology


Dr. Mahmoud Sabry Sallam
Prof. of Clinical Pathology

Dr. Omar Awad
Ass. Prof. of Cardiology

Dr. Gihan Kamal El-Din Hassan
Ass. Prof. of Clinical Pathology

Dr. Nadia Ali Abdel Sattar
Lect. of Clinical Pathology

Faculty of Medicine
Ain Shams University
1990





*Dedicated to :
My Parents
Husband
& Children*

*For Their
& Endurance , Sacrifice , Support
Love.*

Acknowledgment

I would like to express my deepest gratitude and appreciation to Dr. Sawsan Hosney Hamza, Professor of Clinical Pathology, Ain Shams University, for her indispensable guidance and her invaluable suggestions that greatly enriched this work. Without her expert help and her motherly support this work would have never been achieved.

I am greatly indebted to Dr. Mahmoud Sabry Sallam, Professor of Clinical Pathology, Ain Shams University, for offering me a lot of his kind support, vast experience and precious knowledge. I am grateful for his helpful supervision and fruitful criticism.

I am very grateful to Dr. Omar Sallah Awad, Assistant Professor of Cardiology, Ain Shams University, for his continuous, generous, and sincere contributions to this work.

I am much obliged to Dr. Lihan Hassan Aly, Assistant Professor of Clinical Pathology, Ain Shams University, for her valuable supervision expert advice, and her sincere efforts to provide all possible facilities for this work.

My sincere thanks are due to Dr. Nadia Aly Abdel Sattar, Lecturer of Clinical Pathology, Ain Shams University, for her generous honest co-operation, great patience, warm encouragement, and continuous support through every piece of this work.

I am grateful to Dr. Mohamed Abdel-Bary, Assistant Lecturer of Pharmacology, Ain Shams University, for his faithful help in the pharmacokinetic part of this work.

Thanks are also extended to all my colleagues who offered me help, support and encouragement during preparing this thesis.

Dahlia Farag

1990.

TABLE OF CONTENTS

	Page
<u>INTRODUCTION AND AIM OF THE WORK</u>	1
Introduction.	1
Aim of The Work.	2
<u>REVIEW OF LITERATURE</u>	3
Chapter I : <u>Therapeutic Drug Monitoring [TDM]</u>	
A) Historical Background.	3
B) Fundamentals Of TDM.	6
1. Pharmacodynamics.	7
a) Site of drug action.	7
b) Mechanism of drug action.	8
2. Pharmacokinetics.	10
a) Principles of drug disposition.	11
b) Basic pharmacokinetic concepts.	22
c) Principles of pharmacokinetic analysis.	36
d) Pharmacokinetics in clinical practice.	42
C) Clinical Basis For TDM.	47
1. Relation of dosage, serum concentration, and effect.	47
2. Therapeutic range.	48
3. Factors affecting therapeutic response of the patient.	49
4. Clinical utility of TDM.	63

Chapter II : Digoxin

A) History of introduction of digoxin in clinical practice.	66
B) Clinical pharmacology of digoxin.	67
1. Structure and biochemical characteristics.	67
2. Digoxin pharmacodynamics.	68
a) Site of action.	68
b) Mechanism of action.	68
3. Digoxin pharmacokinetics.	70
a) Bioavailability and absorption of digoxin.	70
b) Protein binding and tissue distribution.	72
c) Digoxin metabolism.	74
d) Digoxin excretion.	77
C) Clinical basis for digoxin TDM.	78
1. Factors affecting the therapeutic response to digoxin.	78
2. The clinical applications of serum digoxin measurements.	89
D) Methods of digoxin assay.	93
* Estimation of total digoxin in blood.	93
1. Chromatographic assays.	94
2. The rubidium uptake inhibition assay.	95
3. Immunoassays.	96
a) Types of immunoassays.	96
b) Problems encountered with digoxin immunoassay.	101
* Estimation of free digoxin concentration.	104

MATERIAL AND METHODS

A) Analytical and clinical evaluation studies.	106
B) Study of digoxin-like immunoreactive substances by ELISA.	138
C) Study of digoxin pharmacokinetics.	139
D) Designation of dosing regimen.	141

<u>RESULTS AND DISCUSSION</u>	142
A) Analytical evaluation.	142
1. Reliability characteristics.	142
2. Practicability characteristics.	150
B) Clinical evaluation.	151
1. Determination of the therapeutic range.	151
2. Study of the toxic group of patients.	154
3. Diagnostic value of serum digoxin measurements.	157
C) Pharmacokinetic study.	160
D) Designation of dosing regimen.	162
<u>SUMMARY AND CONCLUSION</u>	165
<u>REFERENCES</u>	173

ARABIC SUMMARY

Figures in the Review of Literature are adopted from Applied Therapeutic Drug Monitoring. Volume I : Fundamentals (Eds.) Moyer T.P. and Boeckxrl. The American Association for Clinical Chemistry. Library of Congress. Washington D.C. [1982].

INTRODUCTION
AND
AIM OF WORK

INTRODUCTION AND AIM OF THE WORK

INTRODUCTION

Digoxin, a cardiac glycoside, is one of the most widely used drugs all over the world. Due to its low toxic/therapeutic ratio, digoxin intoxication persists as one of the most prevalent adverse drug reactions encountered in clinical practice. It has in fact plagued the medical profession for over 200 years. The estimated prevalence of digitalis toxicity among hospitalized patients in the 1970's ranged from 15-30% with significant morbidity and mortality [George, 1983]. At present, the incidence has dropped to lower values but is still alarming [Smith et al., 1988].

The dilemma of the diagnosis of digoxin toxicity and judging the proper therapeutic dosage is faced by many clinicians. It can only be resolved through the increased understanding of the basic clinical pharmacology of cardiac glycosides, and the continuing advances in the field of analytical techniques, both of which form the basis for digoxin therapeutic drug monitoring.

AIM OF THE WORK

The aim of this work included :

- 1- The analytical evaluation of 3 methods for digoxin assay namely radioimmunoassay [RIA], enzyme-linked immunosorbent assay [ELISA], and enzyme multiplied immunoassay technique [EMIT].
- 2- A study of digoxin-like immunoreactive substances [DLIS] in uremic patients.
- 3- Determination of the therapeutic range of serum digoxin for each kit both in patients with normal renal function and in patients with renal impairment.
- 4- Evaluation of the diagnostic value of serum digoxin concentration measurements in suspected digoxin toxicity.
- 5- Estimation of the pharmacokinetic parameters of digoxin in a sample of Egyptian cardiac patients on digoxin therapy with normal hepatic and renal functions.
- 6- Designation of the recommended dosage regimen in cardiac patients with normal hepatic and renal functions.

REVIEW
OF
LITERATURE

REVIEW OF LITERATURE

CHAPTER 1

THERAPEUTIC DRUG MONITORING

Therapeutic drug monitoring [TDM] is the timely measurement of drug concentration in blood and other body fluids and the subsequent evaluation and interpretation of these results. This provides the basis for rational adjustment of drug dosage and scheduling for the benefit of patient management [Marks, 1985].

A. HISTORICAL BACKGROUND

For hundreds of years, appropriate dosage regimen had been established in individual patients by *trial and error*. This trial and error therapy placed both the patient and his physician at the mercy of unknown factor - the kinetics of the drug in that

patient - which resulted in great variations in the therapeutic response [Pippenger, 1982].

The therapeutic regimen depending on the administration of the "usual dose" is also hazardous. The usual dose of most potent drugs may have little effect in some persons, causes serious toxicity in others, and is fully satisfactory in few. Many patients require drug doses higher than the standard dosage schedules to obtain a sufficiently intense pharmacologic effect. On the other hand, other patients develop adverse reactions to drug therapy because the dose is too high for them. The habitual administration of the conventional dose can be satisfactory only when a drug's therapeutic margin is very large, and when its full therapeutic potential is not required [Koch-Weser et al., 1969].

Therapy with potent drugs, becomes safer and more effective when dosage is adjusted to the need and tolerance of each patient [Koch-Weser, 1972]. Consequently, attempts were made to tailor the dosage of drugs to suit individual patients by monitoring their "pharmacologic effects" and increasing or decreasing the dose accordingly. For example, digoxin was "individualized" by counting the pulse rate and / or inquiring about the presence and severity of undesirable side effects. The dose of salicylates was increased in treatment of rheumatic fever until dose dependent side effects ; notably tinnitus ; appeared and then slightly decreased in order to produce maximum therapeutic benefit with minimum or zero toxicity. However, it was appreciated that this method of adjusting dosage was not applicable to all or even to